Quest Diagnostics Incorporated (DGX) : Traders are bullish on Quest Diagnostics Incorporated (DGX) as it has outperformed the S&P 500 by a wide margin of 2.85% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.67%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.6% in the last 1 week, and is up 6.3% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 3.95% and the 50-Day Moving Average is 8.49%. Quest Diagnostics Inc. is up 15.45% in the last 3-month period. Year-to-Date the stock performance stands at 23.36%.
Quest Diagnostics Incorporated (NYSE:DGX): stock turned positive on Friday. Though the stock opened at $85.12, the bulls momentum made the stock top out at $86.44 level for the day. The stock recorded a low of $85.085 and closed the trading day at $86.36, in the green by 1.23%. The total traded volume for the day was 1,471,146. The stock had closed at $85.31 in the previous days trading.
Quest Diagnostics Incorporated is a provider of diagnostic testing information services. The Company consists of two businesses: Diagnostic Information Services and Diagnostic Solutions. Diagnostic Information Services business, consists of two parts, develops and delivers diagnostic testing, information and services to patients, physicians, health plans, hospitals, accountable care organizations (ACOs), integrated delivery networks (IDNs), other commercial laboratories, patients and other customers. Diagnostics Information Services business also provides diagnostic information services, which includes providing clinical testing services, such as routine testing, gene-based and esoteric testing, anatomic pathology services and drugs-of-abuse testing. Diagnostic Solutions includes the Companys other businesses, including central laboratory testing for pharmaceutical and medical device clinical trials, risk assessment services, diagnostic products and healthcare information technology.